<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34592907</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2165-5987</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioengineered</Title>
          <ISOAbbreviation>Bioengineered</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cabergoline possesses a beneficial effect on blood-brain barrier (BBB) integrity against lipopolysaccharide (LPS).</ArticleTitle>
        <Pagination>
          <StartPage>8358</StartPage>
          <EndPage>8369</EndPage>
          <MedlinePgn>8358-8369</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21655979.2021.1987066</ELocationID>
        <Abstract>
          <AbstractText>Sepsis is a disease induced by severe systemic inflammation and contributes to multiple acute organic dysfunctions. It is reported that disrupted blood-brain barrier (BBB) integrity is involved in sepsis-associated encephalopathy (SAE), which can be alleviated by repairing the damaged tight junction structure. Cabergoline is a specific dopamine D2 receptor agonist developed to treat Parkinson's disease and hyperprolactinemia and is reported to exert promising anti-inflammatory properties. The present study aimed to explore the beneficial effect of Cabergoline for the treatment of sepsis. In the animal experiments, mice were separated into 4 groups: sham, LPS (5 mg/kg), Cabergoline (0.1 mg/kg/day), and Cabergoline+LPS. We found that the increased neurological deficits, disrupted BBB integrity, elevated production of inflammatory factors, and declined expression level of zonula occludens-1 (ZO-1) were observed in lipopolysaccharide (LPS)-treated mice, all of which were significantly reversed by the administration of Cabergoline. In the <i>in vitro</i> model, human brain microvascular endothelial cells (HBMECs) were challenged with 1 µg/mL LPS in the presence or absence of Cabergoline (10, 20 μM) for 24 hours. The elevated cell permeability P<sub>app</sub> value of fluorescein disodium across the HBMECs monolayer and declined trans-endothelial electrical resistance (TEER) in the LPS-treated HBMECs were significantly alleviated by Cabergoline, accompanied by the upregulation of ZO-1. In addition, wnt1 and β-catenin were found downregulated, which was reversed by Cabergoline. Importantly, the protective benefits of Cabergoline were all abolished by the overexpression of Dickkopf 3 (DKK3). Taken together, our data reveal that Cabergoline possessed a protective effect on BBB integrity against LPS.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>You</LastName>
            <ForeName>Lina</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gerontology, Traditional Chinese medicine hospital of Jiulongpo District in Chongqing, Chongqing, 400080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Haidong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Chongqing Infectious Disease Medical Center, Chongqing, 400080, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bioengineered</MedlineTA>
        <NlmUniqueID>101581063</NlmUniqueID>
        <ISSNLinking>2165-5979</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C569042">TJP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C569043">Tjp1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062826">Zonula Occludens-1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062826" MajorTopicYN="N">Zonula Occludens-1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">DKK3</Keyword>
        <Keyword MajorTopicYN="Y">LPS</Keyword>
        <Keyword MajorTopicYN="Y">blood-brain barrier</Keyword>
        <Keyword MajorTopicYN="Y">sepsis</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34592907</ArticleId>
        <ArticleId IdType="pmc">PMC8806944</ArticleId>
        <ArticleId IdType="doi">10.1080/21655979.2021.1987066</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Czura CJ.
“Merinoff symposium 2010: sepsis”-speaking with one voice. Mol Med. 2011;17:2–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3022986</ArticleId>
            <ArticleId IdType="pubmed">21246163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change. Lancet. 2013;381:774–775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4535310</ArticleId>
            <ArticleId IdType="pubmed">23472921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23353941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molnar L, Fulesdi B, Nemeth N, et al. Sepsis-associated encephalopathy: a review of literature. Neurol India. 2018;66:352–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29547154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang QH, Sheng ZY, Yao YM.. 
Septic encephalopathy: when cytokines interact with acetylcholine in the brain. Mil Med Res. 2014;1:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340341</ArticleId>
            <ArticleId IdType="pubmed">25722876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang LN, Wang XT, Ai YH, et al. Epidemiological features and risk factors of sepsis-associated encephalopathy in intensive care unit patients: 2008-2011. Chin Med J (Engl). 2012;125:828–831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22490582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishioku T, Dohgu S, Takata F, et al. Detachment of brain pericytes from the basal lamina is involved in disruption of the blood-brain barrier caused by lipopolysaccharide-induced sepsis in mice. Cell Mol Neurobiol. 2009;29:309–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dal-Pizzol F, Tomasi CD, Ritter C. Septic encephalopathy: does inflammation drive the brain crazy?
Braz J Psychiatry. 2014;36:251–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24918523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sankowski R, Mader S, Valdes-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4313590</ArticleId>
            <ArticleId IdType="pubmed">25698933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharshar T, Mazeraud A, Verdonk F, et al. Brain perfusion in sepsis or to resolve the macro part of the micro. Crit Care Med. 2014;42:485–486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24434464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharshar T, Annane D, de la Grandmaison GL, et al. The neuropathology of septic shock. Brain Pathol. 2004;14:21–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8095740</ArticleId>
            <ArticleId IdType="pubmed">14997934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander JJ, Jacob A, Cunningham P, et al. TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Int. 2008;52:447–456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3191465</ArticleId>
            <ArticleId IdType="pubmed">17884256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J, Shen Z, Anraku Y, et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6915305</ArticleId>
            <ArticleId IdType="pubmed">31546096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Chen S, Luo Y, et al. Crosstalk between Inflammation and the BBB in Stroke. Curr Neuropharmacol. 2020;18:1227–1236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7770647</ArticleId>
            <ArticleId IdType="pubmed">32562523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu M, Mei XL, Zhao YN. Sepsis and cerebral dysfunction: BBB damage, neuroinflammation, oxidative stress, apoptosis and autophagy as key mediators and the potential therapeutic approaches. Neurotox Res. 2021;39:489–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32876918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 2002;200:639–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1570752</ArticleId>
            <ArticleId IdType="pubmed">12162731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharshar T, Carlier R, Bernard F, et al. Brain lesions in septic shock: a magnetic resonance imaging study. Intensive Care Med. 2007;33:798–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17377766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greene C, Campbell M. Tight junction modulation of the blood brain barrier: CNS delivery of small molecules. Tissue Barriers. 2016;4:e1138017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4836485</ArticleId>
            <ArticleId IdType="pubmed">27141420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson’s disease. Heart. 2004;90:e47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1768376</ArticleId>
            <ArticleId IdType="pubmed">15253989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakroborty D, Sarkar C, Mitra RB, et al. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res. 2004;10(13):4349–4356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15240521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009;24(5):1025–1035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19189995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Ma L, Wan X, et al. (R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation. Psychopharmacology (Berl). 2021;238(10):2743–2753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34313805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuo K, Sone M, Honda-Kohmo K, et al. Significance of dopamine D1 receptor signalling for steroidogenic differentiation of human induced pluripotent stem cells. Sci Rep. 2017;7(1):1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5680317</ArticleId>
            <ArticleId IdType="pubmed">29123220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Lu M, Mei M, et al. Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection. Nat Commun. 2020;11(1):941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7029000</ArticleId>
            <ArticleId IdType="pubmed">32071304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Y, Zhang B, Eum SY, et al. HIV-1 Tat triggers nuclear localization of ZO-1 via Rho signaling and cAMP response element-binding protein activation. J Neurosci. 2012;32:143–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3566645</ArticleId>
            <ArticleId IdType="pubmed">22219277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y, Desse S, Martinez A, et al. TNFalpha disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain Behav Immun. 2018;69:556–567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5963697</ArticleId>
            <ArticleId IdType="pubmed">29452218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laksitorini MD, Yathindranath V, Xiong W, et al. Impact of Wnt/beta-catenin signaling on ethanol-induced changes in brain endothelial cell permeability. J Neurochem. 2021;157:1118–1137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32998179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang Q, Hu W, Zhang X, et al. Wnt/beta-Catenin signaling pathway-related proteins (DK3, beta-Catenin, and c-MYC) are involved in prognosis of nasopharyngeal carcinoma. Cancer Biother Radiopharm. 2019;34:436–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31025872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avtan SM, Kaya M, Orhan N, et al. The effects of hyperbaric oxygen therapy on blood-brain barrier permeability in septic rats. Brain Res. 2011;1412:63–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21803336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banks WA, Gray AM, Erickson MA, et al. Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. J Neuroinflammation. 2015;12:223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4660627</ArticleId>
            <ArticleId IdType="pubmed">26608623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kikuchi DS, Campos ACP, Qu H, et al. Poldip2 mediates blood-brain barrier disruption in a model of sepsis-associated encephalopathy. J Neuroinflammation. 2019;16:241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6883676</ArticleId>
            <ArticleId IdType="pubmed">31779628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu WY, Wang ZB, Zhang LC, et al. Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. CNS Neurosci Ther. 2012;18:609–615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6493516</ArticleId>
            <ArticleId IdType="pubmed">22686334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol. 2004;190:446–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15530883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honig G, Mader S, Chen H, et al. Blood-Brain barrier deterioration and hippocampal gene expression in polymicrobial sepsis: an evaluation of endothelial MyD88 and the vagus nerve. PLoS One. 2016;11:e0144215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4720404</ArticleId>
            <ArticleId IdType="pubmed">26790027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso FL, Kittel A, Veszelka S, et al. Exposure to lipopolysaccharide and/or unconjugated bilirubin impair the integrity and function of brain microvascular endothelial cells. PLoS One. 2012;7:e35919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3346740</ArticleId>
            <ArticleId IdType="pubmed">22586454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang CH, Kao MC, Shih PC, et al. Simvastatin attenuates sepsis-induced blood-brain barrier integrity loss. J Surg Res. 2015;194:591–598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25534234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haorah J, Heilman D, Knipe B, et al. Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. Alcohol Clin Exp Res. 2005;29:999–1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15976526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han D, Fang W, Zhang R, et al. Clematichinenoside protects blood brain barrier against ischemic stroke superimposed on systemic inflammatory challenges through up-regulating A20. Brain Behav Immun. 2016;51:56–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26231971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vedula SR, Lim TS, Kausalya PJ, et al. Biophysical approaches for studying the integrity and function of tight junctions. Mol Cell Biomech. 2005;2:105–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16708473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liebner S, Corada M, Bangsow T, et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol. 2008;183:409–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2575783</ArticleId>
            <ArticleId IdType="pubmed">18955553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paolinelli R, Corada M, Ferrarini L, et al. Wnt activation of immortalized brain endothelial cells as a tool for generating a standardized model of the blood brain barrier in vitro. PLoS One. 2013;8:e70233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734070</ArticleId>
            <ArticleId IdType="pubmed">23940549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez SH, Fan S, Dykstra H, et al. Inhibition of glycogen synthase kinase 3beta promotes tight junction stability in brain endothelial cells by half-life extension of occludin and claudin-5. PLoS One. 2013;8:e55972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3572160</ArticleId>
            <ArticleId IdType="pubmed">23418486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shailesh H, Siveen KS, Sif S. Protein arginine methyltransferase 5 (PRMT5) activates WNT/beta-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3. J Cell Mol Med. 2021;25:1583–1600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7875925</ArticleId>
            <ArticleId IdType="pubmed">33462997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi M, Cheng L, Hua W, et al. MicroRNA-95-3p promoted the development of prostatic cancer via regulating DKK3 and activating Wnt/beta-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23:1002–1011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30779066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odaka H, Numakawa T, Adachi N, et al. Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PLoS One. 2014;9(6):e99271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4051758</ArticleId>
            <ArticleId IdType="pubmed">24914776</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
